Supira Medical Raises $120M for Ventricular Assist Device Development

Supira Medical has successfully raised $120 million in an oversubscribed Series E funding round, aimed at advancing its percutaneous ventricular assist device (pVAD) technology for patients undergoing high-risk cardiac procedures and experiencing cardiogenic shock. The funding, co-led by new investors Novo Holdings and the Qatar Investment Authority, will support the company's clinical programs, including a pivotal study necessary for FDA premarket approval. Supira's innovative pVAD system, which has already treated patients in South American trials, is designed to temporarily assist heart function through a low-profile catheter pump. The company recently completed enrollment for its U.S. Early Feasibility Study and plans to expand its clinical trials further. Dr. Christopher Shen from Novo Holdings has joined Supira's board, emphasizing the significant unmet need for next-generation ventricular support devices. Overall, this capital infusion reflects investor confidence in Supira's potential to enhance clinical outcomes in cardiac care.